# Chymase Angiotensin-(1-12) Axis In Hypertensive Disease

> **NCT05644769** · PHASE4 · UNKNOWN · sponsor: **Trinity Hypertension & Metabolic Research Institute** · enrollment: 10 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **OTHER:** Determine the presence of Human sequence Ang-(1-12) on no medication
- **DRUG:** Human sequence Ang-(1-12) on Lisinopril 40mg every day

## Key facts

- **NCT ID:** NCT05644769
- **Lead sponsor:** Trinity Hypertension & Metabolic Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-15
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644769, "Chymase Angiotensin-(1-12) Axis In Hypertensive Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05644769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*